InMode Announces Conclusion of Independent Transaction Committee Review

Core Viewpoint - InMode Ltd. has concluded its independent transaction committee review and determined that none of the final proposals for a potential transaction are adequate for the company and its shareholders, leading to the discontinuation of the process [1] Group 1: Transaction Review - The independent transaction committee of InMode's Board of Directors has completed its review of proposals related to a potential transaction [1] - The committee conducted a comprehensive evaluation with the assistance of external financial and legal advisors [1] - Following the review, the committee concluded that the proposals received were not in the best interests of the company and its shareholders [1] Group 2: Future Strategy - InMode will continue to assess its business and growth strategy, as well as its cash allocation strategy, focusing on enhancing long-term shareholder value [1] - The company does not plan to provide further updates on this matter unless additional disclosure is deemed appropriate or required [1] Group 3: Company Overview - InMode is a leading global provider of innovative medical technologies, developing, manufacturing, and marketing devices that utilize novel radio frequency technology [1] - The company aims to enable new surgical procedures and improve existing treatments across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [1]